Earnings Results to Track: UroGen Pharma Ltd. (NASDAQ: URGN)

On 17 Jan 2020, UroGen Pharma Ltd. (NASDAQ: URGN) changed -2.17% to recent value of $33.85. The stock transacted 244943 shares during most recent day however it has an average volume of 171.09K shares. It spotted trading -38.60% off 52-week high price. On the other end, the stock has been noted 63.37% away from the low price over the last 52-weeks.

UroGen Pharma Ltd. (URGN) recently reported financial results for the third quarter ended September 30, 2019 and provided an overview of the Company’s recent developments.

Third Quarter 2019 Financial Results; 2019 Guidance

As of September 30, 2019, cash, cash equivalents and marketable securities totaled $221.7M.

Research and development expenses for the three months ended September 30, 2019 were $9.5M, including non-cash share-based compensation expense of $2.1M. Research and development expenses for the nine months ended September 30, 2019 were $29.2M, including non-cash share-based compensation expense of $6.4M.

General and administrative expenses for the three months ended September 30, 2019 were $14.0M, including non-cash share-based compensation expense of $5.2M. General and administrative expenses for the nine months ended September 30, 2019 were $40.5M, including non-cash share-based compensation expense of $15.5M.

The Company stated a net loss of $22.3M, or basic and diluted net loss per ordinary share of $1.06, for the three months ended September 30, 2019. The Company stated a net loss of $66.2M, or basic and diluted net loss per ordinary share of $3.25, for the nine months ended September 30, 2019.

Including the recently reported Agenus deal, the Company is still on track to end the year with a net loss for the year in the range of $100 to $110M, which is predictable to include non-cash stock-based compensation expense in the range of $28 to $30M, subject to market conditions.

The company has 19.69M of outstanding shares and 18.53M shares were floated in the market. According to the most recent quarter its current ratio was 11.3 that represents company’s ability to meet its current financial obligations. The price moved ahead of 2.51% from the mean of 20 days, 9.67% from mean of 50 days SMA and performed 5.12% from mean of 200 days price. Company’s performance for the week was 7.26%, 4.51% for month and YTD performance remained 1.44%.

 

Leave a Reply

Your email address will not be published. Required fields are marked *